BREXAFEMME

Peak

ibrexafungerp citrate

GSK
NDAORALTABLETPriority Review
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
0/100

Loss of Exclusivity

LOE Date
Jun 10, 2039
161 months away
Patent Expiry
Jun 10, 2039
Exclusivity Expiry
Jun 1, 2031

Patent Records (5)

Patent #ExpiryTypeUse Code
8188085
Aug 28, 2030
SubstanceProduct
U-3159
10174074
Jan 19, 2035
SubstanceProduct
—
10370406
Jan 19, 2035
U-3159
10927142
Jan 19, 2035
Substance
—
11534433
Jun 10, 2039
U-3508
Company
GSK
GSK
LONDON, United Kingdom
695 open jobs
External Resources
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers